G01N 33/5758
Involving compounds serving as markers for tumours, cancers or neoplasias
Official title: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
G01N33/5758 (Involving compounds serving as markers for tumours, cancers or neoplasias) appears on 4,758 US grants and 9,897 published applications in this corpus.
Search patents in G01N- Granted patents
- 4,758
- Published applications
- 9,897
- Assignees
- 3,010
- Inventors
- 15,091
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 5 | 0 |
| 1980 | 5 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 2 | 0 |
| 1984 | 3 | 0 |
| 1985 | 1 | 0 |
| 1986 | 6 | 0 |
| 1987 | 7 | 0 |
| 1988 | 3 | 0 |
| 1989 | 8 | 0 |
| 1990 | 6 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 14 | 0 |
| 1994 | 17 | 0 |
| 1995 | 20 | 0 |
| 1996 | 23 | 0 |
| 1997 | 48 | 0 |
| 1998 | 63 | 0 |
| 1999 | 77 | 0 |
| 2000 | 51 | 0 |
| 2001 | 54 | 18 |
| 2002 | 48 | 140 |
| 2003 | 37 | 1169 |
| 2004 | 35 | 204 |
| 2005 | 47 | 198 |
| 2006 | 82 | 256 |
| 2007 | 188 | 233 |
| 2008 | 193 | 209 |
| 2009 | 86 | 264 |
| 2010 | 153 | 290 |
| 2011 | 126 | 258 |
| 2012 | 122 | 291 |
| 2013 | 152 | 310 |
| 2014 | 163 | 493 |
| 2015 | 209 | 497 |
| 2016 | 230 | 519 |
| 2017 | 256 | 505 |
| 2018 | 274 | 472 |
| 2019 | 338 | 478 |
| 2020 | 298 | 460 |
| 2021 | 246 | 530 |
| 2022 | 247 | 519 |
| 2023 | 201 | 459 |
| 2024 | 213 | 444 |
| 2025 | 240 | 373 |
| 2026 | 152 | 308 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Means and methods for the diagnosis, classification and/or monitoring of pediatric tumors6 Oct 2026US 12,754,186 B2Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Molecular profiling of tumors6 Oct 2026US 12,754,193 B2Caris MPI, Inc.
- Diagnosis, prognosis and treatment of malignant neoplasms29 Sep 2026US 12,748,114 B2Rhode Island Hospital
- Methods of determining risk of and treating cancer recurrence22 Sep 2026US 12,742,782 B2The Regents of the University of Michigan
- Cancer diagnostic15 Sep 2026US 12,736,537 B2The Council of the Queensland Institute of Medical Research
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Compositions and methods for determining the effects of t cell engager8 Oct 2026US 2026/0309708 A1Arbele Limited
- Compositions and methods for detection of aberrant cdk5 expression8 Oct 2026US 2026/0309712 A1Arizona Board of Regents on Behalf of the University of Arizona
- Combination therapy of polio virus receptor inhibitors and fucose8 Oct 2026US 2026/0309713 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Immunohistochemistry (ihc) protocols and methods for diagnosing and treating cancer - claudin 18.28 Oct 2026US 2026/0309714 A1Agilent Technologies, Inc.
Most cited
By later US patents
- Antibodies to human programmed death receptor PD-1454US 8,354,509 B2MSD Oss B.V. · 2013
- Computer assisted methods for diagnosing diseases342US 5,769,074 AHorus Therapeutics, Inc. · 1998
- Methods and reagents for the rapid and efficient isolation of circulating cancer cells288US 6,365,362 B1Board of Regents, The University of Texas System · 2002
- Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders222US 7,763,420 B2Genelux Corporation · 2010
- Computer assisted methods for diagnosing diseases213US 6,248,063 B1Horus Therapeutics, Inc. · 2001